Premium
Premature physeal closure following 13‐ cis ‐retinoic acid and prolonged fenretinide administration in neuroblastoma
Author(s) -
Steineck Angela,
MacKenzie John D.,
Twist Clare J.
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26124
Subject(s) - medicine , fenretinide , retinoic acid , neuroblastoma , administration (probate law) , closure (psychology) , cancer research , endocrinology , retinoid , genetics , biology , gene , cell culture , political science , economics , law , market economy
Retinoid therapy has contributed to improved outcomes in neuroblastoma. Clinical trials of fenretinide report favorable toxicity and disease stabilization in patients with high risk (HR) neuroblastoma. Skeletal effects have been described with other retinoids, but not with fenretinide to date. Two patients with HR, metastatic, refractory neuroblastoma received protracted courses of oral fenretinide for more than 5 years’ duration. Both developed premature long bone physeal closure, causing limb length discrepancies; their neuroblastoma remains in remission. The radiographic and clinical findings reported suggest these skeletal abnormalities may be a consequence of treatment with 13‐ cis ‐retinoic acid (13 cis RA) followed by prolonged oral fenretinide exposure.